A single plasmid was engineered to direct the transcription of shRNAs against c-myc, VEGF, hTERT, and BIRC5, which encodes Survivin. This produced a more effective anti-cancer effect than shRNA plasmids targeting individual oncogenes [96]. The gene discussed is BIRC5; the disease is cancer.